Ren Yamada

发表

Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19

N. Sakamoto, M. Natsuizaka, A. Kubo, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Overestimated renal function in patients with liver cirrhosis predicts poor prognosis

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2021, Nutrients.

Changes in the estimated renal function after hepatitis C virus eradication with direct‐acting antiviral agents: Impact of changes in skeletal muscle mass

N. Sakamoto, M. Natsuizaka, T. Sho, 2021, Journal of viral hepatitis.

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2022, Cancers.

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma

N. Sakamoto, M. Natsuizaka, Masaru Baba, 2021, PloS one.

Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma

N. Sakamoto, M. Natsuizaka, T. Sho, 2020, JGH open : an open access journal of gastroenterology and hepatology.

The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease

T. Sugiyama, N. Sakamoto, S. Ohnishi, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria

T. Miyagishima, N. Sakamoto, S. Ohnishi, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C

N. Sakamoto, M. Natsuizaka, M. Nishida, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2021, Cancers.

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

T. Miyagishima, N. Sakamoto, S. Ohnishi, 2022, Cancers.

Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan

A. Homma, T. Abe, H. Hata, 2020, Journal of gastroenterology and hepatology.

Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma

N. Sakamoto, T. Sho, K. Morikawa, 2022, World journal of hepatology.

Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection

N. Shinohara, N. Sakamoto, M. Natsuizaka, 2022, Journal of viral hepatitis.

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients

N. Sakamoto, T. Sho, K. Morikawa, 2022, PloS one.

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2021, Scientific Reports.

Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients

M. Sugiyama, M. Mizokami, N. Sakamoto, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Durable response without recurrence to Tolvaptan improves long-term survival

N. Sakamoto, A. Kubo, T. Sho, 2020, Journal of Gastroenterology.

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication

N. Sakamoto, Masaru Baba, Yoshiya Yamamoto, 2022, Scientific Reports.

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B

N. Sakamoto, M. Natsuizaka, Yoshiya Yamamoto, 2022, PloS one.

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy

M. Natsuizaka, A. Kubo, T. Sho, 2021, World journal of gastrointestinal oncology.

Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis

N. Sakamoto, S. Ohnishi, M. Natsuizaka, 2023, Journal of medical virology.

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

N. Sakamoto, M. Natsuizaka, M. Nishida, 2021, Scientific Reports.

Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection

H. Miyoshi, A. Nakamura, N. Sakamoto, 2020, Journal of Gastroenterology.

Case Report: Hereditary Fibrosing Poikiloderma With Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Presenting With Liver Cirrhosis and Steroid-Responsive Interstitial Pneumonia

S. Konno, T. Nomura, N. Sakamoto, 2022, Frontiers in Genetics.

The First Case of Hereditary Fibrosing Poikiloderma with Tendon Contractures, Myopathy, and Pulmonary Fibrosis (POIKTMP) Who Showed Efficacy of Corticosteroids for Pulmonary Involvement

H. Shimizu, S. Konno, T. Nomura, 2020 .

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment

T. Miyagishima, N. Sakamoto, S. Ohnishi, 2022, Liver Cancer.

Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis

T. Sho, K. Morikawa, Koji Ogawa, 2023, Journal of Gastroenterology.

Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR 1-3 signaling, but not FGFR4 signaling.

M. Sugiyama, M. Mizokami, N. Sakamoto, 2020, Carcinogenesis.